Ramamoorthy S, Giovanetti E, Qian Y, et al. 1998. Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. J Biol Chem, 273:2458–66. Ranade K, Jorgenson E, Sheu WH, et al. 2002. A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet, 70:935–42. Rasenick MM, Chaney KA, Chen J. 1996. G protein-mediated signal transduction as a target of antidepressant and antibipolar drug action: evidence from model systems. J Clin Psychiatry, 57:49–55. Rausch JL, Gillespie CF, Fei Y, et al. 2002. Antidepressant effect on kinase gene expression patterns in rat brain. Neurosci Lett, 334:91–4. Rausch JL, Johnson ME, Fei Y-J, et al. 2002. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry, 51:723–32. Raymond JR, Mukhin YV, Gelasco A, et al. 2001. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Therap, 92:179–212. Redrobe JP, Bourin M. 1997. Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol, 325:129–35. Riccio A, Ahn S, Davenport CM, et al. 1999. Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science, 286:2358–61. Richards JG, Saura J, Luque JM, et al. 1998. Monoamine oxidases: from brain maps to physiology and transgenics to pathophysiology. J Neural Transm, 52(Suppl):173–87. Robinson-White A, Stratakis C. 2002. Protein kinase A signaling: “cross- talk” with other pathways in endocrine cells. Ann N Y Acad Sci, 968:256–70. Rogoz Z, Skuza G, Maj J, et al. 2002. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology, 42:1024–30. Rosin DL, Melia K, Knorr AM, et al. 1995. Chronic imipramine administration alters the activity and phosphorylation state of tyrosine hydroxylase in dopaminergic regions of rat brain. Neuropsycho- pharmacology, 12:113–21. Rosmond R, Bouchard C, Bjorntorp P. 2002. A C-1291G polymorphism in the alpha2A-adrenergic receptor gene (ADRA2A) promoter is associated with cortisol escape from dexamethasone and elevated glucose levels. J Intern Med, 251:252–7. Rosmond R, Chagnon M, Bouchard C, et al. 2001. A polymorphism in the regulatory region of the corticotropin-releasing hormone gene in relation to cortisol secretion, obesity, and gene-gene interaction. Metab Clin Exp, 50:1059–62. Rujescu D, Giegling I, Sato T, et al. 2003. Genetic variations in tryptophan hydroxylase in suicidal behavior: analysis and meta-analysis. Biol Psychiatry, 54:465–73. Rumajogee P, Madeira A, Verge D, et al. 2002. Up-regulation of the neuronal serotoninergic phenotype in vitro: BDNF and cAMP share Trk B-dependent mechanisms. J Neurochem, 83:1525–8. Saarelainen T, Hendolin P, Lucas G, et al. 2003. Activation of the trkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci, 23:349–57. Sabol SZ, Hu S, Hamer D. 1998. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet, 103:273–9. Sachidanandam R, Weissman D, Schmidt SC, et al. 2001. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature, 409:928–33. Saito N, Shirai Y. 2002. Protein kinase C gamma (PKC gamma): function of neuron specific isotype. J Biochem, 132:683–7. Sanacora G, Rothman DL, Mason G, et al. 2003. Clinical studies implementing glutamate neurotransmission in mood disorders. Ann N Y Acad Sci, 1003:292–308. Candidate genes for SSRI response Sanders AR, Duan J, Gejman PV. 2002. DNA variation and psychopharmacology of the human serotonin receptor 1B (HTR1B) gene. Pharmacogenomics, 3:745–62. Santarelli L, Saxe M, Gross C, et al. 2003. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science, 301:805–9. Sato K, Yoshida K, Takahashi H, et al. 2002. Association between -1438G/ A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology, 46:136–40. Saura J, Bleuel Z, Ulrich J, et al. 1996. Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience, 70:755–74. Schaefer ML, Wong ST, Wozniak DF, et al. 2000. Altered stress-induced anxiety in adenylyl cyclase type VIII-deficient mice. J Neurosci, 20:4809–20. Schatzberg AF, Garlow SJ, Nemeroff CB. 2002. Molecular and cellular mechanisms in depression. In Davis KL, Charney D, Coyle JT, et al (eds). Neuropsychopharmacology: the fifth generation of progress. Philadelphia: Lippincott Williams & Wilkins. p 1039–50. Schulze TG, Hardy J, McMahon FJ. 2003. Inconsistent designs of association studies: a missed opportunity. Mol Psychiatry, 8:770–2. Scott JD. 1997. Dissection of protein kinase and phosphatase targeting interactions. Soc Gen Physiol Ser, 52:227–39. Selinger-Leneman H, Genin E, Norris JM, et al. 2003. Does accounting for gene-environment (GxE) interaction increase the power to detect the effect of a gene in a multifactorial disease? Genet Epidemiol, 24:200–7. Serretti A, Franchini L, Gasperini M, et al. 1998. Mode of inheritance in mood disorders families according to fluvoxamine response. Acta Psychiatr Scand, 98:443–50. Serretti A, Lilli R, Smeraldi E. 2002. Pharmacogenetics in affective disorders. Eur J Pharmacol, 438:117–28. Serretti A, Lorenz C, Cusin C, et al. 2003. SSRIs antidepressant activity is influenced by G beta 3 variants. Eur Neuropsychopharmacol, 13: 117–22. Serretti A, Zanardi R, Cusin C, et al. 2001a. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol, 11:375–80. Serretti A, Zanardi R, Cusin C, et al. 2001b. No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. Psychiatry Res, 104:195–203. Serretti A, Zanardi R, Rossini D, et al. 2001. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry, 6:586–92. Shaffery J, Hoffmann R, Armitage R. 2003. The neurobiology of depression: perspectives from animal and human sleep studies. Neuroscientist, 9:82–98. Sheehan TP, Neve RL, Duman RS, et al. 2003. Antidepressant effects of the calcium-activated tyrosine kinase Pyk2 in the lateral septum. Biol Psychiatry, 54:540–51. Sheline YI. 2003. Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry, 54:338–52. Shelton RC. 2000. Intracellular mechanisms of antidepressant drug action. Harv Rev Psychiatry, 8:161–74. Shelton RC, Manier D, Sulser F. 1996. cAMP-dependent protein kinase activity in major depression. Am J Psychiatry, 153:1037–42. Shirayama Y, Chen AC-H, Nakagawa S, et al. 2002. Brain derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci, 22:3251–61. Shytle RD, Silver AA, Lukas RJ, et al. 2002. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry, 7:525–35. Sim AT, Scott JD. 1999. Targeting of PKA, PKC and protein phosphatases to cellular microdomains. Cell Calcium, 26:209–17. Neuropsychiatric Disease and Treatment 2005:1(1) 33